Inhibitor Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INTI research report →
Companywww.inhibitortx.com
Inhibitor Therapeutics, Inc. , a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome.
- CEO
- Francis E. O'Donnell Jr.
- IPO
- 2013
- Employees
- 3
- HQ
- Tampa, FL, US
Price Chart
Valuation
- Market Cap
- $13.81M
- P/E
- -4.12
- P/S
- 0.00
- P/B
- -6.98
- EV/EBITDA
- -3.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 525.87%
- ROIC
- -319.23%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,300,337 · 1.16%
- EPS
- $-0.02 · 1.55%
- Op Income
- $-3,426,653
- FCF YoY
- 0.05%
Performance & Tape
- 52W High
- $0.12
- 52W Low
- $0.04
- 50D MA
- $0.09
- 200D MA
- $0.06
- Beta
- -0.23
- Avg Volume
- 20.71K
Get TickerSpark's AI analysis on INTI
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Apr 1, 25 | Vasisht Niraj | other | 50,000 |
| Apr 1, 25 | Yanez Michelle | other | 50,000 |
| Apr 1, 25 | SEARS SAMUEL P JR | other | 50,000 |
| Apr 1, 25 | OSMAN RONALD E | other | 50,000 |
| Apr 1, 25 | Jerman Michael Allen | other | 50,000 |
| Dec 31, 24 | MCNULTY JAMES A | other | 0 |
| Dec 31, 24 | Yanez Michelle | other | 0 |
| Apr 1, 24 | Yanez Michelle | other | 50,000 |
| Mar 16, 24 | MCNULTY JAMES A | other | 100,000 |
| Apr 1, 24 | SEARS SAMUEL P JR | other | 50,000 |
Our INTI Coverage
We haven't published any research on INTI yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate INTI Report →